INTRODUCTION: Zero-dose prevalence refers to children who failed to receive any routine vaccination. Little is known about the "immunisation cascade" in low- and middle-income countries (LMICs), defined as how children move from zero dose to full immunisation. METHODS: Using data from national surveys carried out in 92 LMICs since 2010 and focusing on the four basic vaccines delivered in infancy (BCG, polio, DPT and MCV), we describe zero-dose prevalence and the immunisation cascade in children aged 12 to 23 months. We also describe the most frequent combinations of vaccines (or co-coverage) among children who are partially immunized. Analyses are stratified by country income groups, household wealth quintiles derived from asset indices, sex of the child and area of residence. Results were pooled across countries using child populations as weights. RESULTS: In the 92 countries, 7.7% were in the zero-dose group, and 3.3%, 3.4% and 14.6% received one, two or three vaccines, respectively; 70.9% received the four types and 59.9% of the total were fully immunised with all doses of the four vaccines. Three quarters (76.8%) of children who received the first vaccine received all four types. Among children with a single vaccine, polio was the most common in low- and lower-middle income countries, and BCG in upper-middle income countries. There were sharp inequalities according to household wealth, with zero-dose prevalence ranging from 12.5% in the poorest to 3.4% in the wealthiest quintile across all countries. The cascades were similar for boys and girls. In terms of dropout, 4% of children receiving BCG did not receive DPT1, 14% receiving DPT1 did not receive DPT3, and 9% receiving DPT3 did not progress to receive MCV. INTERPRETATION: Focusing on zero-dose children is particularly important because those who are reached with the first vaccine are highly likely to also receive remaining vaccines.
INTRODUCTION: Zero-dose prevalence refers to children who failed to receive any routine vaccination. Little is known about the "immunisation cascade" in low- and middle-income countries (LMICs), defined as how children move from zero dose to full immunisation. METHODS: Using data from national surveys carried out in 92 LMICs since 2010 and focusing on the four basic vaccines delivered in infancy (BCG, polio, DPT and MCV), we describe zero-dose prevalence and the immunisation cascade in children aged 12 to 23 months. We also describe the most frequent combinations of vaccines (or co-coverage) among children who are partially immunized. Analyses are stratified by country income groups, household wealth quintiles derived from asset indices, sex of the child and area of residence. Results were pooled across countries using child populations as weights. RESULTS: In the 92 countries, 7.7% were in the zero-dose group, and 3.3%, 3.4% and 14.6% received one, two or three vaccines, respectively; 70.9% received the four types and 59.9% of the total were fully immunised with all doses of the four vaccines. Three quarters (76.8%) of children who received the first vaccine received all four types. Among children with a single vaccine, polio was the most common in low- and lower-middle income countries, and BCG in upper-middle income countries. There were sharp inequalities according to household wealth, with zero-dose prevalence ranging from 12.5% in the poorest to 3.4% in the wealthiest quintile across all countries. The cascades were similar for boys and girls. In terms of dropout, 4% of children receiving BCG did not receive DPT1, 14% receiving DPT1 did not receive DPT3, and 9% receiving DPT3 did not progress to receive MCV. INTERPRETATION: Focusing on zero-dose children is particularly important because those who are reached with the first vaccine are highly likely to also receive remaining vaccines.
Authors: Peter A Maple; Alberto Ascherio; Jeffrey I Cohen; Gary Cutter; Gavin Giovannoni; Claire Shannon-Lowe; Radu Tanasescu; Bruno Gran Journal: Front Neurol Date: 2022-06-24 Impact factor: 4.086
Authors: Huda Ahmed Ali; Anna-Maria Hartner; Susy Echeverria-Londono; Jeremy Roth; Xiang Li; Kaja Abbas; Allison Portnoy; Emilia Vynnycky; Kim Woodruff; Neil M Ferguson; Jaspreet Toor; Katy Am Gaythorpe Journal: Int J Equity Health Date: 2022-06-11
Authors: Thiago M Santos; Bianca O Cata-Preta; Tewodaj Mengistu; Cesar G Victora; Daniel R Hogan; Aluisio J D Barros Journal: EClinicalMedicine Date: 2021-11-06
Authors: Andrea Wendt; Thiago M Santos; Bianca O Cata-Preta; Janaína C Costa; Tewodaj Mengistu; Daniel R Hogan; Cesar G Victora; Aluísio J D Barros Journal: J Glob Health Date: 2022-03-26 Impact factor: 4.413
Authors: Nicole Bergen; Bianca O Cata-Preta; Anne Schlotheuber; Thiago M Santos; M Carolina Danovaro-Holliday; Tewodaj Mengistu; Samir V Sodha; Daniel R Hogan; Aluisio J D Barros; Ahmad Reza Hosseinpoor Journal: Vaccines (Basel) Date: 2022-04-18
Authors: Courtney Emerson; Jed Meline; Anne Linn; Julie Wallace; Bryan K Kapella; Meera Venkatesan; Richard Steketee Journal: Glob Health Sci Pract Date: 2022-04-29